Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway

Revolution Medicines (RVMD) remains a 'Strong Buy' following statistically significant phase 3 RASolute 302 results for daraxonrasib in 2nd-line metastatic PDAC. Company's daraxonrasib achieved median overall survival of 13.2 months vs. 6.7 months for chemotherapy in the ITT population [p < 0.0001]. Expansion opportunities include phase 3 RASolute 303 for 1st-line PDAC and additional late-stage trials in NSCLC and adjuvant settings.